Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

A. Powell, Matthew; Cibula, David; M. O’Malley, David; Boere, Ingrid; S. Shahin, Mark; Savarese, Antonella; M. Chase, Dana; Gilbert, Lucy; Black, Destin; Herrstedt, Jørn; Sharma, Sudarshan; Kommoss, Stefan; A. Gold, Michael; M.J. Thijs, Anna; L. Ring, Kari; Frödin Bolling, Magnus; Buscema, Joseph; Gill, Sarah; Nowicki, Paul; Nevadunsky, Nicole; J. Callahan, Michael; Willmott, Lyndsay; K. McCourt, Carolyn; C. Billingsley, Caroline; Ghamande, Sharad; He, Zangdong; Marco Balas, Morad; Stevens, Shadi; Fleming, Evelyn; Raza Mirza, Mansoor

doi:10.1016/j.ygyno.2024.10.022

Public

Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Published in Gynecologic Oncology • Nov 12, 2024

Authors:

Matthew A. Powell

David Cibula

David M. O’Malley

Abstract

OBJECTIVES: Part 1 of the RUBY trial (NCT03981796) demonstrated improved survival in patients with primary advanced or recurrent endometrial cancer (EC) treated with dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel. Here, we examine additional efficacy and safety da...

Subject

Medicine

Endometrial cancer

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!